John Hill, MD
Hematology & Oncology · Hendersonville, NCNPI 1780646992
Payments from drug & device makers
Across 131 payments — averaging $132.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- AstraZeneca$213
- Seagen Inc.$208
- Pfizer$179
- Astellas Pharma US Inc$174
- Genentech USA, Inc.$134
- plus $1K from 34 others
What the payments were for
- Food & beverage$1,93079%
- Education$52021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $15,273 |
| AstraZeneca(2 entities) | 8 | $213 |
| Seagen Inc. | 3 | $208 |
| Pfizer | 15 | $179 |
| Astellas Pharma US Inc | 5 | $174 |
| Genentech USA, Inc. | 9 | $134 |
| Novartis | 6 | $111 |
| E.r. Squibb & Sons, L.L.C. | 7 | $110 |
| Bristol Myers Squibb | 6 | $89 |
| Gilead(2 entities) | 4 | $80 |
| Sanofi | 3 | $65 |
| Merck | 4 | $63 |
| Incyte Corporation | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $56 |
| Lilly USA, LLC | 3 | $50 |
| Johnson & Johnson(2 entities) | 3 | $48 |
| Puma Biotechnology, Inc. | 3 | $46 |
| Novocure Inc. | 3 | $46 |
| Dendreon Pharmaceuticals LLC | 2 | $45 |
| AbbVie | 2 | $39 |
| GE HealthCare | 1 | $28 |
| Kyowa Kirin, Inc. | 2 | $27 |
| Beigene USA, Inc. | 1 | $21 |
| Tesaro, Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Verastem, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
| Partner Therapeutics, Inc. | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $14 |
| Cardinal Health 414 LLC | 1 | $14 |
| Bayer | 1 | $14 |
| Convatec Inc. | 1 | $12 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| ADC Therapeutics America, Inc. | 1 | $12 |
| Array Biopharma Inc | 1 | $11 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
How this compares
$17,410 in reported general payments places this provider in the 55th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 25 | $482,902 |
| PomalystPomalidomide | 14 | $347,486 |
| ImbruvicaIbrutinib | 20 | $314,671 |
| JakafiRuxolitinib Phosphate | 24 | $265,357 |
| LorbrenaLorlatinib | 11 | $236,138 |
| PromactaEltrombopag Olamine | 12 | $158,665 |
| XareltoRivaroxaban | 40 | $30,624 |
| EliquisApixaban | 16 | $14,503 |
| Anastrozole | 144 | $2,622 |
| Letrozole | 64 | $1,799 |
| Anagrelide Hcl | 11 | $1,516 |
| ValacyclovirValacyclovir Hcl | 15 | $1,295 |
| Ibandronate Sodium | 34 | $1,076 |
| Hydroxyurea | 27 | $852 |
| Tamoxifen Citrate | 20 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $89 | $482,90225 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $110 | $347,48614 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $11 | $314,67120 claims |
| Incyte CorporationJakafi | $57 | $265,35724 claims |
| PfizerLorbrena, Eliquis | $179 | $250,64127 claims |
| NovartisPromacta | $111 | $158,66512 claims |
| Johnson & JohnsonXarelto | $48 | $30,62440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Hendersonville
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Shelbi AtrashCharlotte$9.5M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
- Michael MorseDurham$6M
- Autumn McReeChapel Hill$5.5M
- Darla LilesGreenville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.